MAIA director granted 26,355 stock options

MAIA Biotechnology director Theagene Jean-Manasse received a new stock option grant as equity compensation.

Rhea-AI Filing Summary

MAIA Biotechnology director Theagene Jean-Manasse received a new stock option grant as equity compensation. The grant covers 26,355 stock options, each allowing the purchase of common stock at an exercise price of $1.44 per share. According to the disclosure, these options vest 100% on the grant date of June 30, 2026 and are exercisable beginning that same day. Following this award, the filing shows 26,355 derivative securities held, indicating this is a new option position rather than a sale or open-market purchase of shares.

Insider Trade Summary

Grant/Award: 26,355 shares

Grant/Award 1 txn

Insider Theagene Jean-Manasse

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Options	26,355	$0.00	$0.00

Holdings After Transaction: Stock Options — 26,355 contracts (Direct)

Footnotes (1)

1. F1. The stock options, granted on June 30, 2026 pursuant to the MAIA Biotechnology, Inc's 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest 100% on the date of the grant and are exercisable beginning as of that date.

Key Figures

Stock options granted: 26,355 options Exercise price: $1.44 per share Underlying shares: 26,355 shares +3 more

6 metrics

Stock options granted 26,355 options Grant to director on June 30, 2026

Exercise price $1.44 per share Stock option strike price

Underlying shares 26,355 shares Common stock underlying granted options

Total derivatives after grant 26,355 options Derivative holdings following transaction

Vesting schedule 100% on grant date Options vest fully on June 30, 2026

Expiration date June 30, 2036 Option term under 2021 Equity Incentive Plan

Key Terms

2021 Equity Incentive Plan, stock options, vest 100% on the date of the grant, exercisable

4 terms

2021 Equity Incentive Plan financial

"granted on June 30, 2026 pursuant to the MAIA Biotechnology, Inc's 2021 Equity Incentive Plan"

stock options financial

"The stock options, granted on June 30, 2026 pursuant to the MAIA Biotechnology, Inc's 2021 Equity Incentive Plan"

Stock options are agreements that give a person the right to buy or sell a company's stock at a specific price within a certain time frame. They are often used as a reward or incentive, similar to a coupon that can be used later if the stock price rises, allowing the holder to make a profit.

vest 100% on the date of the grant financial

"representing the right to buy shares of common stock, vest 100% on the date of the grant"

exercisable financial

"vest 100% on the date of the grant and are exercisable beginning as of that date"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did MAIA (MAIA) director Theagene Jean-Manasse report in this Form 4 filing?

The filing reports a grant of 26,355 stock options to director Theagene Jean-Manasse. These options are compensation, not an open-market trade, and give the right to buy MAIA common stock at a fixed exercise price.

How many MAIA (MAIA) stock options were granted and at what exercise price?

Theagene Jean-Manasse was granted 26,355 stock options with an exercise price of $1.44 per share. Each option represents the right to purchase one share of MAIA common stock at that fixed price.

When do the newly granted MAIA (MAIA) stock options vest and become exercisable?

The options vest 100% on the grant date of June 30, 2026. The footnote states they are exercisable beginning as of that date, meaning the director can exercise all granted options immediately after vesting.

How long does Theagene Jean-Manasse have to exercise these MAIA (MAIA) options?

The options expire on June 30, 2036, giving a ten-year exercise window. Until that expiration date, the director may choose when to exercise, subject to the company’s plan rules and any applicable trading restrictions.

Are these MAIA (MAIA) option transactions open-market buys or routine compensation?

The transaction is a routine compensation grant under MAIA Biotechnology’s 2021 Equity Incentive Plan. The Form 4 classifies it as a grant or award acquisition, not an open-market purchase or sale of common shares.

What is Theagene Jean-Manasse’s derivative position in MAIA (MAIA) after this grant?

After the grant, the filing shows 26,355 derivative securities held, all from this stock option award. There are no additional derivative holdings listed, indicating this represents the director’s reported option position at that time.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/02/2026 - 04:09 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Theagene Jean-Manasse

(Last) (First) (Middle)

444 WEST LAKE STREET, SUITE 1700

(Street)

CHICAGO ILLINOIS 60606

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
MAIA Biotechnology, Inc. [ MAIA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/30/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Options	$1.44	06/30/2026		A		26,355		06/30/2026(1)	06/30/2036	Common Stock	26,355	$0	26,355	D

Explanation of Responses:

1. The stock options, granted on June 30, 2026 pursuant to the MAIA Biotechnology, Inc's 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest 100% on the date of the grant and are exercisable beginning as of that date.

	/s/ Jean-Manasse Theagene	07/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)